CD5-targeted CAR-T immunotherapy Trials

CD5-targeted CAR-T immunotherapy

Welcome, Profile Billing Logout

Companies

5 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

ICG124 / iCell Gene Therap

CD5CAR-T, NCT04594135: Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

Recruiting

RoW

anti-CD5 CAR T cells

iCell Gene Therapeutics, iCAR Bio, Peking University Shenzhen Hospital

T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma

11/23

RD125 / IASO BIO

NCT04767308: Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Not yet recruiting

CT125A cells, Cyclophosphamide, fludarabine

Huazhong University of Science and Technology, Shanghai IASO Biotechnology Co., Ltd

CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Peripheral T-cell Lymphomas (PTCL)

09/23

12/23

MB-105 / March Bio

NCT06534060: MB-105 in Patients With CD5 Positive T-cell Lymphoma

Recruiting

Genetic: MB-105

March Biosciences Inc

Lymphoma, T-Cell

02/28

12/29

MAGENTA, NCT03081910: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

Recruiting

Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells

Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)

T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia

01/26

09/40

CD5 CAR T (CT125B) / Beijing Boren Hospital

NCT05487495: Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

Withdrawn

RoW

CD5 CAR T (CT125B)

Beijing Boren Hospital

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

12/23

CD5 CAR-T / Vor Biopharma

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

ICG124 / iCell Gene Therap

CD5CAR-T, NCT04594135: Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

Recruiting

RoW

anti-CD5 CAR T cells

iCell Gene Therapeutics, iCAR Bio, Peking University Shenzhen Hospital

T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma

11/23

RD125 / IASO BIO

NCT04767308: Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Not yet recruiting

CT125A cells, Cyclophosphamide, fludarabine

Huazhong University of Science and Technology, Shanghai IASO Biotechnology Co., Ltd

09/23

12/23

MB-105 / March Bio

NCT06534060: MB-105 in Patients With CD5 Positive T-cell Lymphoma

Recruiting

Genetic: MB-105

March Biosciences Inc

Lymphoma, T-Cell

02/28

12/29

MAGENTA, NCT03081910: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

Recruiting

Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells

Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)

T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia

01/26

09/40

CD5 CAR T (CT125B) / Beijing Boren Hospital

NCT05487495: Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

Withdrawn

RoW

CD5 CAR T (CT125B)

Beijing Boren Hospital

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

12/23

CD5 CAR-T / Vor Biopharma

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites